Abstract: The present invention relates to a method treating or preventing disorders caused by a spiral urease-positive gram-negative bacterium such as Helicobacter pylori in mammals, including humans, using compounds that are substance P receptor antagonists and, specifically, using certain quinuclidine derivatives, piperidine derivatives, pyrrolidine derivatives, azanorbornane derivatives, ethylene diamine derivatives and related compounds.

Abstract: An infection with Helicobacter may successfully be treated with a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or methyl and R.sub.2 is hydrogen or L-alanine-L-alanyl, and the pharmaceutically acceptable acid additive salts thereof. These compounds are useful in the treatment of gastric and duodenal ulcers.

Abstract: Ground germinated rice or an extract of polished rice or germinated rice are effective in preventing or treating ulcers.

Abstract: The use is described of both (i) ranitidine bismuth citrate and (ii) one or more Helicobacter pylori-inhibiting antibiotics in treating or preventing gastrointestinal disorders.Pharmaceutical compositions containing both (i) and (ii) and methods for the preparation of pharmaceutical compositions containing (i) and (ii) are also described.

Abstract: An acetamide derivative having the general formula (I): ##STR1## or a pharmacologically acceptable salt thereof; a synthetic intermediate of the above-mentioned acetamide derivative; a treating agent for peptic ulcer and for gastritis which comprises the above-mentioned compound having the general formula (I) as an effective ingredient, and a process for treating peptic ulcer and gastritis using the above-mentioned compound having the general formula (I), are disclosed.

Abstract: The use is described of both (i) ranitidine bismuth citrate and (ii) one or more Helicobacter pylori-inhibiting antibiotics in treating or preventing gastrointestinal disorders.Pharmaceutical compositions containing both (i) and (ii) and methods for the preparation of pharmaceutical compositions containing (i) and (ii) are also described.

Abstract: The invention relates to pharmaceutical compositions in the form of pleasant-tasting chewable tablets or chewable coated tablets which, besides the pharmaceutically active ingredient sucralfate, essentially contain at least one rapidly swellable physiologically acceptable gel former plus sugars or sugar substitutes.

Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.

Abstract: The use is described of both (i) ranitidine bismuth citrate and (ii) one or more Helicobacter pylori-inhibiting antibiotics in treating or preventing gastrointestinal disorders.Pharmaceutical compositions containing both (i) and (ii) and methods for the preparation of pharmaceutical compositions containing (i) and (ii) are also described.

Abstract: A composition for treating and/or inhibiting gastric and duodenal ulcers, comprising an oligosaccharide selected from the group consisting of Formula I ##STR1## or a mixture thereof; wherein:X is independently OH or NHAc;Y is independently H, or an amino acid or a peptide of 2-100, preferably 2-20, amino acids; andW, W', and W" are each independently H or ##STR2## where Z is independently H or a pharmaceutically acceptable cation; and P is independently H or ##STR3## where Z is defined as above; wherein at least one of W, W' or W" is an .alpha.-N-acetylneuraminic acid moiety, andwherein W' and W" are not simultaneously .alpha.-N-acetylneuraminic acid moietywith the proviso that the compound of Formula II is not NAN .alpha.(2.fwdarw.3)Gal .beta.1-4 Glu or NAN .alpha.(2.fwdarw.6)Gal .beta.1-4 Glu; and a kit for detecting the presence of Helicobacter pylori comprising at least one compound of the Formula I or II, are described.

Abstract: The present invention is directed to a method for the treatment of Helicobacter pylori infection wherein a composition containing protease and an antibacterial agent as active ingredients, which can remove Helicobacter pylori from a stomach at high probability without causing side effects or the occurrence of resistant bacteria, and which can treat and prevent peptic ulcer caused by Helicobacter pylori infection and can prevent the recurrence of peptic ulcer is employed.

Abstract: The present invention provides a method for aiding healing or preventing the onset of intestinal wounds or ulcers in a patient. In addition, the present invention provides a method for reducing, or preventing, the gastrointestinal side effects associated with the administration of a nonsteroidal anti-inflammatory drug. Pursuant to the present invention, the composition includes a protein source, a carbohydrate source, a fat source, and a specialized vitamin and mineral profile.

Abstract: The invention is based on the use of a tellurium compound to treat or prevent gastritis or peptic ulcer. The tellurium compounds may be administered orally or parenterally to a host who is afflicted with or is susceptible to these conditions.

Abstract: The invention relates to the use of an organic extract of the plant Cinnamon or a chemical constituent present in said plant, to prepare a pharmaceutical composition useful to inhibit the growth of Helicobacter pylori and the urease activity of Helicobacter pylori. Most preferred chemical constituents are cinnamaldehyde and methoxycinnamaldehyde. The extract may be used either as a drink, with or without additional flavoring ingredients or transformed into a capsule. The invention also relates to in-vitro method for determininig the inhibition of urease activity of Helicobacter pylori using said organic extract of the plant or chemical constituents present in said plant.

Abstract: A method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma, inflammation or shock by administering an effective amount of a PAF antagonist of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5 ; R.sup.5 is an unsubstituted or substituted C.sub.6 -C.sub.14 carbocyclic aryl of an aromatic heterocyclic having from 5 to 14 ring atoms, of which from 1 to 5 are hetero-atoms selected from the group consisting of nitrogen, oxygen and sulfur, the heterocyclic group being unsubstituted or substituted; R.sup.3 is hydrogen, a C.sub.1 -C.sub.6 alkyl, cyano, or --R.sup.5 ; X is oxygen or sulfur; A is a 1,4-piperazin-1,4-diyl or a 1,4-homopiperazin-1,4-diyl; B is a C.sub.1 -C.sub.6 alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl; and R.sup.4 is an unsubstituted or substituted phenyl group.

Abstract: A preparation containing an aluminum salt of a sucrose sulfate ester (sucralfate) and polyethylene glycol, and a process for preparation of the same are disclosed. Sucralfate is extensively used as a curative for digestive ulcers and has the capability of protecting the substrate protein. Sucralfate is mixed with polyethylene glycol to provide it with improved disintegrability and dispersibility and this renders sucralfate more useful as a medicine.

Abstract: A method for promoting digestibility of a food product having an acid character which, when ingested, causes stimulation and hypersecretion of gastric and/or duodenum mucosae. The method comprises incorporating into the food product a sufficient amount of benzimidazole or a benzimidazole compound of the formula: ##STR1## where X and Y independently represent an alkyl group, a phenyl group or a halogen atom and n=1 to 4.

Abstract: The invention relates to novel, pharmaceutically active trisubstituted cycloalkane derivatives, a process for the preparation thereof and pharmaceutical compositions comprising the same. The invention also encompasses the use of the said cycloalkane derivatives for the treatment of diseases and for the preparation of pharmaceutical compositions suitable for the treatment of diseases.The compounds according to the invention are characterized by the general formula (I), ##STR1## wherein R represents hydrogen, C.sub.1-4 alkyl or hydroxyl,R.sup.1 stands for C.sub.1-12 alkyl,R.sup.2 and R.sup.3 each represents hydrogen, C.sub.1-12 alkyl or C.sub.2-12 alkenyl, orR.sup.2 and R.sup.3 together with the adjacent nitrogen atom form a 4- to 7-membered ring optionally comprising an oxygen, sulfur or a further nitrogen atom, which latter may carry a phenyl, benzyl or C.sub.1-4 alkyl substituent,R.sup.4 and R.sup.5 each stands for hydrogen, halogen or C.sub.

Abstract: The invention is related to the field of treating gastric and duodenal disorders and more specifically to the use of certain 13,14-dihydro-prostaglandin E derivatives, especially of PGE.sub.2, which are modified to contain a ring structure in the omega chain. The invention relates also to pharmaceutical compositions containing an active amount of these derivatives.

Abstract: The invention relates to the use of either an aqueous extract or an organic extract of the plant Thymus to prepare a pharmaceutical composition useful to inhibit the growth of Helicobacter pylori and the urease activity of Helicobacter pylori. In case of an aqueous extract, a minimum amount of 0.5 mg of the dry plant in the extract is required but the preferred amounts are above 1.2 mg. The aqueous extract may be used either as a drink, with or without additional ingredients, or transformed into a capsule or a paste. The invention also relates to in-vitro methods for inhibiting the growth of the urease activity of Helicobacter pylori.

Abstract: The present invention relates to a method for enhancing white blood cell functioning and metabolism on a mucosal surface of a mammal. The present invention also relates to a method for treating or preventing a condition in a mammal caused by the presence of a disease-causing agent on a mucosal surface or a cutaneous surface wherein the disease-causing agent can be diminished by the actions of the white blood cells. The present invention yet also relates to a method for healing a wound of a mucosal or cutaneous surface. The present invention also relates to compositions for use in such methods.

Abstract: The invention relates to a pharmaceutical composition, which is useful in the treatment of gastrointestinal disorders, especially gastric ulcer, duodenal ulcer and gastritis. The pharmaceutical composition is composed of Rhizoma coptidis extract, Radix scutellariae extract, and Radix astragali extract. Processes for producing these components are provided.

Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.

Abstract: This invention relates to a pharmaceutical composition for treating the symptoms of overindulgence comprising an analgesic effective amount of acetaminophen or a non-steroidal anti-inflammatory drug and a gastric acid inhibiting effective amount of an H.sub.1 or H.sub.2 blocker, proton pump inhibitor or a combination thereof and methods of treating the symptoms of overindulgence comprising administering such pharmaceutical compositions.

Abstract: This invention describes pharmaceutical compositions and methods of treating ulcerating diseases of the gastrointestinal tract in mammals with an acid-resistant fibroblast growth factor compositions. Also described is the use of acid-resistant fibroblast growth factor compositions in the treatment of various other fibroblast growth factor-responsive conditions.

Abstract: Method of promoting healing of a wound by administering turmeric to a patient afflicted with the wound.

Abstract: The subject invention relates to methods for preventing or treating damage to the mucosal lining of the gastrointestinal tract of a human or lower animal by administering a safe and effective amount of a compound having the structure: ##STR1## wherein X and Y are each independently selected from O and S; R.sup.1, R.sup.2 and R.sup.3 are each independently selected from hydrogen, hydroxy, halo, unsubstituted or monosubstituted straight or branched C.sub.1 -C.sub.4 alkanyl, and unsubstituted or substituted straight or branched C.sub.1 -C.sub.4 alkanoxy; and each of R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is hydrogen or, if one or more of R.sup.1, R.sup.2 and R.sup.3 is other than hydrogen, each of R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is selected from hydrogen, halo, trifluoromethyl, and unsubstituted straight or branched C.sub.1 -C.sub.4 alkanyl.

Abstract: Pharmaceutical formulations comprise (i) microcapsules which consist essentially of a biocompatible polymeric wall material encapsulating a drug, and (ii) a lipid soluble surfactant which is mixed with the microcapsules or is incorporated within or coats the wall material of the microcapsules. Such formulations may be presented as an aerosol or dry powder for inhalation. Microcapsules with surfactant incorporated in the wall material may be suspended in a pharmaceutically acceptable water-immiscible oil and the resulting suspension emulsified in an aqueous medium to obtain a formulation for oral administration.

Abstract: A trialkylamine derivative represented by the formula (1) or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different from each other and each represents lower alkyl;R.sup.3, R.sup.4 and R.sup.5 may be the same or different from one another and each represents hydrogen, lower alkyl, lower alkoxy, lower alkoxycarbonyl or halogen;R.sup.6 and R.sup.7 may be the same or different from each other and each represents hydrogen or lower alkyl;R.sup.8 represents hydrogen, lower alkyl, lower alkoxy or halogen;X represents oxygen, sulfur, --CH.dbd.N-- or --CH.dbd.CH--;Y represents oxygen, sulfur, methylene, N--R.sup.11 (wherein R.sup.11 represents lower alkyl), SO or SO.sub.2 ;Z represents --OCO(CH.sub.2).sub.p .about. or --OCH.sub.2 (CH.sub.2).sub.p .about. (wherein p represents a number of 0 to 4 and symbol .about.

Abstract: The diosmin heptakis (hydrogensulfate) aluminum complex is described, as l as its preparation procedure, characterized by reacting one mole of diosmin with seven moles of a sulfating agent in a dry medium and treatment with an aqueous aluminum hydroxycloride solution of the diosmin heptakis (hydrogensulfate) sodium salt thus obtained. A description of pharmacological assays carried out to confirm the cytoprotective action of the product is included.

Abstract: The invention provides compounds of the general formula (I) ##STR1## or a physiologically acceptable salt or solvate thereof, wherein Q represents a 1- or 2-naphthalenyl group.The compounds have a stimulant action at .beta..sub.2 -adrenoreceptors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

Abstract: Medical materials for use in treating maladies in living beings, such as ulcers and other conditions of the digestive tract. In one form, a container is provided for a medication which container also contains an adhesive material which is operatively released from the container or exposed at the surface thereof upon biodegradation or dissolution of a protective coating or wall portion of the container under the effects of fluid in the digestive tract in which the container is exposed, such as by swallowing, to permit such adhesive to temporarily bond and retain the container at a select location in the digestive tract so that it may slowly release its contents thereafter to a select portion of the digestive tract. In another form, a multitude of microcapsules, each containing a small quantity of medication, is mixed with an adhesive material, such as a sucralfate other material which may be swallowed as a tablet or dissolved in a liquid such as water.

Abstract: Compositions and methods for protecting the luminal lining against gastric acid challenge are disclosed. The compositions provide effective anti-ulcer preparations which include phosphorylated alcohol. Phosphorylated alcohols comprise the active anti-ulcerogenic ingredient of the described therapeutic formulations. The preparation of unique linear and cyclic polyphosphorylated alcohols and methods of using same to protect the stomach luminal lining against acid challenge are also disclosed. Inositol hexaphosphate and mannitol hexaphosphate are demonstrated to provide therapeutic value in the treatment and prevention of gastro-erosive disease precipitated by exposure of biological tissues to highly acidic substances, for example, the gastric digestive acids. While inositol hexaphosphate alone at subthreshold concentrations provides a small gastro-protective activity, a combination of inositol hexaphosphate (at subthreshold concentrations) with polyvalent cations, such as Au.sup.+3 or Bi.sup.

Abstract: Methods, for the treatment of humans and lower animal subjects having a gastrointestinal disorder, comprising administering bismuth and administering an antimicrobial. From about 50 to about 5000 milligrams of bismuth are administered, per day, for from 3 to 56 days. A safe and effective amount of antimicrobial is administered for from 1 to 21 days. Preferred processes also include a step for performing a diagnostic test on the subject for detection of a campylobacter-like organism infection of the subject. The invention also provides compositions containing a safe and effective amount of bismuth and a safe and effective amount of antimicrobial.

Abstract: A liquid internal medicine for domestic animals contains only an extract from stems of natural Stevia plants. The medicine is effective for curing disorders of the digestive organs of domestic animals and for improving the physical constitution of domestic animals to further result in improvement of meat quality, milk quality and hair gloss of domestic animals and promotion of the estrous cycle and their establishment of the menstrual function. The medicine contains a liquid obtained by fermenting a concentrate of an extract from Stevia stems, and is administered to domestic animals as is or after dilution. As the medicine contains only the natural component, it is free of any side effects when applied to domestic animals.

Abstract: A liquid internal medicine contains only an extract from stems of natural Stevia plants. The medicine is particularly effective for curing disorders of the digestive organs. The medicine contains a liquid obtained by fermenting a concentrate of an extract from Stevia stems, and is administered to patients as is or after dilution. As the medicine contains only the natural component, it is free of any side effects when applied to patients.

Abstract: The invention relates to a method of arresting and treating duodenal and gastric ulcers, and chronic gastritis comprising administering an effective amount of [4S(4.alpha.,4a.alpha.,5a.alpha.,12a.alpha.)]-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 2a-tetrahydroxy-1,11-dioxo-2-napthacenecarboxymide monohydrochloride.

Abstract: Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12;Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group;R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4;and the physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients.The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.

Abstract: The invention relates to a method of preventing or treating gastrointestinal ulcer disease and microvascular injury in a mammal comprising administering to said mammal a pyrazole derivative alone or in combination with an ulcerogenic agent. The invention further relates to pharmaceutical compositions comprising a pyrazole derivative in combination with an ulcerogenic therapeutic agent to inhibit or prevent the ulcerogenic effect of that agent.

Abstract: The invention is related to the field of treating gastric and duodenal disorders and more specifically to the use of certain 13,14-dihydro-prostaglandin E derivatives, especially of PGE.sub.2, which are modified to contain a ring structure in the omega chain. The invention relates also to pharmaceutical compositions containing an active amount of these derivatives.

Abstract: This invention relates to omeprazole compositions designed for administration in the rectum, wherein said compositions comprise omeprazole, an active ingredient, a mixture of polyethylene glycols having molecular weights 1,000, 1,540, 4,000 and/or 6,000 or a mixture of adeps solidus and sodium laurylsulfate and a soluble, basic amino acid selected from arginine, lysine or histidine.

Abstract: The bitter taste of ranitidine may be masked by forming an adsorbate with a synthetic cation exchange resin. The adsorbate is particularly suitable for use in pharmaceutical compositions for oral administration such as chewable or suckable tablets, granules and aqueous or non-aqueous suspensions.

Abstract: This invention relates to a pharmaceutical composition for treating the symptoms of overidulgence comprising an analgesic effective amount of acetaminophen or a non-steroidal anti-inflammatory drug and a gastric acid inhibiting effective amount of an H.sub.1 or H.sub.2 blocker, proton pump inhibitor or a combination thereof and methods of treating the symptoms of overindulgence comprising administering such pharmaceutical compositions.

Abstract: Therapeutically useful thioformamide derivatives of the formula: ##STR1## wherein R represents alkyl, Ar represents optionally substituted phenyl group, Y represents ethylene, methylene or a valency bond, and X represents carbonyl, hydroxymethylene, >C.dbd.NOR.sup.1, >C.dbd.NN(R.sup.1).sub.2 or >C.dbd.NN(R.sup.1)CON(R.sup.1).sub.2 in which R.sup.1 represents hydrogen or optionally substituted alkyl, benzyl, phenethyl, 1-naphthylmethyl, 2-naphthylmethyl or pyrid-3-ylmethyl or two R.sup.1 substituents on the same nitrogen atom may together form optionally substituted alkylene, and salts thereof, processes for their preparation and compositions containing them are described.

Abstract: This invention describes pharmaceutical compositions and methods of treating ulcerating diseases of the gastrointestinal tract in mammals with an acid-resistant fibroblast growth factor compositions. Also described is the use of acid-resistant fibroblast growth factor compositions in the treatment of various other fibroblast growth factor-responsive conditions.

Abstract: Derivatives of 2-amino-1-phenylethanol were prepared from substituted amines and benzoin, stilbene oxide or styrene oxide to give compounds of Formula: ##STR1## where R is H or (un)substituted phenyl and C is a linking group or terminal group. The compounds of this invention can inhibit ulceration in in-vivo studies in rats.

Abstract: Complexes of sucralfate with alpha cyclodextrin, beta cyclodextrin, gamma cyclodextrin or 2-hydroxypropyl beta cyclodextrin are disclosed. Also disclosed are a process for producing complexes and compositions and a method for reducing gastric injury, employing the complexes.

Abstract: Provided are cycloheptenopyridine derivatives represented by the general formula ##STR1## [wherein R represents a hydrogen atom or lower alkyl group; R.sup.1 represents a hydrogen atom, halogen atom, lower cycloalkoxy group, amido group, substituted phenoxy group, substituted benzyloxy group, lower alkoxy group optionally containing halogen atoms(s), nitro group, hydroxyl group, lower alkenyloxy group, lower alkylthio group, or a group--NR.sup.4 R.sup.5 (wherein R.sup.4 and R.sup.5 may be the same or different and each represent a hydrogen atom or lower alkyl group, or R.sup.4 and R.sup.5 mutually combine together with the nitrogen atom adjacent thereto to form a 5- or 6-membered heterocyclic group); R.sup.2 represents a hydrogen atom, halogen atom, lower alkyl group optionally containing a halogen atom, lower alkoxy group optionally containing a halogen atom, hydroxyl group, acyl group, lower alkoxycarbonyl group, nitro group or amino group; R.sup.

Abstract: Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12;Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group;R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and the physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients.The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.

Abstract: Dimethylpolysiloxane is effective in the treatment of ulcers of the gastrointestinal tract.